151 related articles for article (PubMed ID: 8593128)
1. Lipoproteins and the progression/regression of atherosclerosis.
Barth JD
Baillieres Clin Endocrinol Metab; 1995 Oct; 9(4):849-66. PubMed ID: 8593128
[TBL] [Abstract][Full Text] [Related]
2. Pixel or death: experience from clinical trials assessing lipid lowering therapy.
Barth JD
Can J Cardiol; 1995 May; 11 Suppl C():9C-14C. PubMed ID: 7750051
[TBL] [Abstract][Full Text] [Related]
3. [Is regression of atherosclerosis possible?].
Thomas D; Richard JL; Emmerich J; Bruckert E; Delahaye F
Arch Mal Coeur Vaiss; 1992 Oct; 85 Spec No 3():47-57. PubMed ID: 1296545
[TBL] [Abstract][Full Text] [Related]
4. Reversibility of atherosclerosis--evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study.
Hodis HN
J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S25-31. PubMed ID: 8907211
[TBL] [Abstract][Full Text] [Related]
5. Progression and regression of the atherosclerotic plaque.
de Feyter PJ; Vos J; Deckers JW
Eur Heart J; 1995 Aug; 16 Suppl I():26-30. PubMed ID: 8829954
[TBL] [Abstract][Full Text] [Related]
6. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness.
Hodis HN; Mack WJ; Dunn M; Liu C; Liu C; Selzer RH; Krauss RM
Circulation; 1997 Apr; 95(8):2022-6. PubMed ID: 9133510
[TBL] [Abstract][Full Text] [Related]
7. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
Rackley CE
Clin Cardiol; 1996 Sep; 19(9):683-9. PubMed ID: 8874986
[TBL] [Abstract][Full Text] [Related]
8. George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal.
Blankenhorn DH; Hodis HN
Arterioscler Thromb; 1994 Feb; 14(2):177-92. PubMed ID: 8305407
[TBL] [Abstract][Full Text] [Related]
9. Triglyceride-rich lipoproteins and progression of atherosclerosis.
Hodis HN; Mack WJ
Eur Heart J; 1998 Feb; 19 Suppl A():A40-4. PubMed ID: 9519342
[TBL] [Abstract][Full Text] [Related]
10. Plasma lipoproteins and coronary arteriography in subjects in the program on the surgical control of the hyperlipidemias. Preliminary report.
Moore RB; Long JM; Matts JP; Amplatz K; Varco RL; Buchwald H
Atherosclerosis; 1979 Feb; 32(2):101-19. PubMed ID: 222301
[TBL] [Abstract][Full Text] [Related]
11. Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials.
de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():257-63. PubMed ID: 9211018
[TBL] [Abstract][Full Text] [Related]
12. Role of risk factor management in progression and regression of coronary and femoral artery atherosclerosis.
Glueck CJ
Am J Cardiol; 1986 May; 57(14):35G-41G. PubMed ID: 3521250
[TBL] [Abstract][Full Text] [Related]
13. Relationship of angiographically defined coronary artery disease to serum lipoproteins and apolipoproteins in young survivors of myocardial infarction.
Hamsten A; Walldius G; Szamosi A; Dahlen G; de Faire U
Circulation; 1986 Jun; 73(6):1097-110. PubMed ID: 3698244
[TBL] [Abstract][Full Text] [Related]
14. Biology of cholesterol, lipoproteins and atherosclerosis.
Havel RJ
Clin Exp Hypertens A; 1989; 11(5-6):887-900. PubMed ID: 2676261
[TBL] [Abstract][Full Text] [Related]
15. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.
Hodis HN; Mack WJ; Azen SP; Alaupovic P; Pogoda JM; LaBree L; Hemphill LC; Kramsch DM; Blankenhorn DH
Circulation; 1994 Jul; 90(1):42-9. PubMed ID: 8026027
[TBL] [Abstract][Full Text] [Related]
16. IDL composition and angiographically determined progression of atherosclerotic lesions during simvastatin therapy.
Sutherland WH; Restieaux NJ; Nye ER; Williams MJ; de Jong SA; Robertson MC; Walker HL
Arterioscler Thromb Vasc Biol; 1998 Apr; 18(4):577-83. PubMed ID: 9555863
[TBL] [Abstract][Full Text] [Related]
17. Regression of coronary atherosclerosis: an achievable goal? Review of results from recent clinical trials.
Waters D; Lespérance J
Am J Med; 1991 Jul; 91(1B):10S-17S. PubMed ID: 1867231
[TBL] [Abstract][Full Text] [Related]
18. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
Eur Heart J; 1996 Dec; 17 Suppl F():37-42. PubMed ID: 8960446
[TBL] [Abstract][Full Text] [Related]
19. Diabetic dyslipidemia.
Kreisberg RA
Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein oxidation and progression of carotid atherosclerosis.
Salonen JT; Nyyssönen K; Salonen R; Porkkala-Sarataho E; Tuomainen TP; Diczfalusy U; Björkhem I
Circulation; 1997 Feb; 95(4):840-5. PubMed ID: 9054740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
